文献速递妇产影像介入MR

症状性子宫肌瘤磁共振引导聚焦超声手术前单剂量促性腺激素释放激素激动剂给药的有效性

Efficacy of single-dose gonadotropin-releasing hormone agonist administration prior to magnetic resonance-guided focused ultrasound surgery for symptomatic uterine fibroids.
PubMed 文献 · Radiol Med · 2017-03-24

本先导研究在17例患者共20个肌瘤中于MRgFUS前单剂量给予GnRHa,并与回顾性纳入的17例患者19个肌瘤对照,比较非灌注体积和热剂量学。给药约29天后肌瘤SSI和体积分别降低55.1%和10.6%(p<0.05),GnRHa组单位能量NPV更大、SSI更低,两者呈负相关(p=0.011)。作者认为单剂量GnRHa可能提高MRgFUS治疗效率。

要点

  • MRgFUS前单剂量GnRHa约29天后肌瘤SSI降低55.1%、体积降低10.6%(p<0.05)。
  • GnRHa组单位能量NPV为0.046 cm3/J±0.026,大于对照组的0.031 cm3/J±0.018(p=0.041)。
  • GnRHa组SSI为8.4±8.0,低于对照组13.9±12.0(p=0.053),未达统计学显著。

核心结论

  • GnRHa被认为可减少肌瘤包括血管在内的液体内容并增强组织对热能的反应性;MRgFUS前单剂量给药有潜力提高治疗效率,同时避免多剂量GnRHa的副作用。

研究设计与样本

  • 先导研究,GnRHa组17例患者共20个肌瘤,单剂量GnRHa后前瞻性系列MR扫描随访体积和标化信号强度(SSI);对照组17例患者19个肌瘤为回顾性纳入,比较非灌注体积(NPV)和热剂量学。

关键影像表现/征象

  • GnRHa给药约29天后,肌瘤SSI降低55.1%、体积降低10.6%(p<0.05),未报告不良事件。
  • GnRHa组SSI为8.4±8.0,低于对照组13.9±12.0(p=0.053),未达统计学显著。

诊断标准与关键数值

  • GnRHa组单位能量NPV为0.046 cm3/J±0.026,大于对照组0.031 cm3/J±0.018(p=0.041)。
  • 线性回归分析显示单位能量NPV与SSI呈负相关(p=0.011)。

临床应用与阅片要点

  • SSI作为反映肌瘤液体内容的客观指标,可在MRgFUS术前系列MR扫描中用于评估GnRHa对肌瘤的影响。
  • 单位能量NPV与SSI呈负相关,提示SSI较低时单位能量获得的非灌注体积可能更大(作者解释)。

局限性

  • 本研究为先导研究,GnRHa组样本为17例患者共20个肌瘤。
  • 对照组为回顾性纳入。
  • SSI组间比较p=0.053,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the effects of a single-dose GnRHa on the thermal ablation of MRgFUS in women with symptomatic fibroids.

MATERIALS AND METHOD: In this pilot study, a single-dose GnRHa was administered in 17 patients with a total of 20 fibroids. Volume and scaled signal intensity (SSI) as an objective marker of fluid contents were prospectively followed up with serial MR scans. The control group of 17 patients with 19 fibroids were retrospectively enrolled and compared with GnRHa group in terms of non-perfused volume (NPV) and thermal dosimetry to assess the efficiency of thermal ablation.

RESULTS: About 29 days after GnRHa administration, SSI and volume of fibroids were reduced by 55.1 and 10.6%, respectively (p < 0.05) but no adverse events were reported. NPV per unit energy (0.046 cm3/J ± 0.026 vs. 0.031 cm3/J ± 0.018, p = 0.041) was larger and SSI (8.4 ± 8.0 vs. 13.9 ± 12.0, p = 0.053) was lower in GnRHa group. Linear regression analysis showed that these two parameters were in a reverse correlation (p = 0.011).

CONCLUSION: GnRHa is supposed to reduce the fluid contents of fibroids including blood vessels and enhance the tissue responsiveness to thermal energy. A single dose prior to MRgFUS has the potential to improve treatment efficiency, while avoiding the side effects of multiple doses of GnRHa.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Park H, Yoon SW. Efficacy of single-dose gonadotropin-releasing hormone agonist administration prior to magnetic resonance-guided focused ultrasound surgery for symptomatic uterine fibroids. Radiol Med. 2017. PMID: 28341966. doi:10.1007/s11547-017-0754-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。